Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $32.39 USD
Change Today -0.59 / -1.79%
Volume 62.3K
VASC On Other Exchanges
As of 3:49 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

vascular solutions inc (VASC) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/15 - $40.33
52 Week Low
11/17/14 - $22.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

vascular solutions inc (VASC) Related Businessweek News

No Related Businessweek News Found

vascular solutions inc (VASC) Details

Vascular Solutions, Inc., a medical device company, provides various solutions to interventional cardiologists, interventional radiologists, electro physiologists, and vein practices worldwide. The company’s catheter products include GuideLiner catheters for use in various interventions; Pronto extraction catheters for treating acute myocardial infarction; Micro-Introducers for performing arterial and venous catheterization procedures; Langston to measure intravascular pressure gradients for the diagnosis of aortic valve stenosis; and SmartNeedle, a doppler-guided needle device designed to provide auditory ultrasound-guided access to arteries and veins. It also offers Venture, a deflectable tip catheter used for steering guidewires in various interventions; Guardian, a hemostat valve to allow placement of multiple devices simultaneously; SuperCross, a catheter for support and delivery of guidewires during coronary and peripheral interventions; Snares to retrieve or manipulate devices in catheterization procedures; and Minnie, a support catheter used to facilitate placement and exchange of guidewires and other interventional devices. In addition, the company provides hemostat products comprising D-Stat Dry Thrombix, a thrombin-based hemostat bandage used in conjunction with manual compression to control bleeding in catheterizations; D-Stat Flowable, a flowable mixture to control bleeding in the pectoral pockets; Vasc Band, a compression device that utilizes an inflatable membrane to control bleeding; D-Stat Radial, a compression device that utilizes a thrombin pad to control bleeding; and accumed wrist positioning splint. Further, it offers vein products and services, such as Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, as well as a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The company was founded in 1996 and is headquartered in Minneapolis, Minnesota.

485 Employees
Last Reported Date: 02/3/15
Founded in 1996

vascular solutions inc (VASC) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $525.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $280.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: $196.0K
Senior Vice President of International Sales
Total Annual Compensation: $285.0K
Vice President of Marketing
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

vascular solutions inc (VASC) Key Developments

Vascular Solutions, Inc. Expands PolarCath Peripheral Dilatation System Product Line with Launch of 11 Versions of 0.035 Guidewire-Compatible Balloon Catheters

Vascular Solutions Inc. announced that it has expanded the PolarCath peripheral dilatation system product line with the launch of 11 versions of 0.035 guidewire-compatible balloon catheters in collaboration with NuCryo Vascular LLC. As previously announced, Vascular Solutions entered into an agreement with NuCryo in November of 2014 to serve as the exclusive U.S. distributor of the PolarCath product line and in March of this year 2015 Vascular Solutions launched 21 versions of 0.014 guidewire-compatible balloon catheters for use with the PolarCath system. The PolarCath peripheral dilatation system is indicated for use in dilating stenoses in the peripheral vasculature (iliac, femoral, popliteal, infrapopliteal, renal, and subclavian arteries) and for the treatment of obstructive lesions of polytetrafluoroethylene access grafts or arteriovenous dialysis fistulae. The PolarCath system is also indicated for post-deployment stent expansion of self-expanding peripheral vascular stents. The PolarCath peripheral dilatation system consists of a balloon catheter, an inflation unit, and a nitrous oxide cartridge. Use of the PolarCath system simultaneously dilates and modifies atherosclerotic plaque. Once delivered to the lesion, the PolarCath balloon is inflated with nitrous oxide gas, which cools the vessel wall during a 20-second treatment at -10°C. The PolarCath peripheral dilatation system was invented by Dr. James Joye, a prominent interventional cardiologist focused on pioneering new vascular treatments.

Vascular Solutions Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Third Quarter and Full Year 2015

Vascular Solutions Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $37,550,000 against $30,677,000 a year ago. Operating earnings was $5,648,000 against $5,031,000 a year ago. Earnings before income taxes were $5,662,000 against $5,030,000 a year ago. Net earnings were $3,727,000 or $0.21 per diluted share against $3,205,000 or $0.18 per diluted share a year ago. Non-GAAP adjusted operating earnings were $7,918,000 or $0.29 per diluted share against $5,717,000 or $0.21 per diluted share a year ago. During the second quarter, the company generated $3.4 million in cash from operations and used $2.6 million for capital expenditures related to building improvements and the purchase of manufacturing, computer, and research and development equipment. For the six months, the company reported total revenue of $72,161,000 against $60,584,000 a year ago. Operating earnings was $9,071,000 against $9,402,000 a year ago. Earnings before income taxes were $9,113,000 against $9,403,000 a year ago. Net earnings were $5,934,000 or $0.33 per diluted share against $6,003,000 or $0.34 per diluted share a year ago. Non-GAAP adjusted operating earnings were $13,774,000 or $0.50 per diluted share against $10,604,000 or $0.39 per diluted share a year ago. For the third quarter of 2015, Vascular Solutions is providing guidance for net revenue of between $36.0 million and $37.0 million, which at the mid-point represents growth of more than 14% from $31.9 million in the third quarter of 2014. The company is providing adjusted net earnings guidance for the third quarter of 2015 of between $0.24 and $0.26 per fully diluted share. The company's adjusted net earnings guidance for the third quarter of 2015 includes $1.0 million in non-cash stock-based compensation, $400,000 in amortization of intangibles, $400,000 for the U.S. medical device excise tax, and an assumed 36% effective income tax rate. For the full year 2015, Vascular Solutions is raising its guidance for net revenue to a range of $145 million to $147 million. The mid-point of this range represents an increase of nearly 16% from net revenue of $126.1 million in 2014. The company's previous net revenue guidance range for 2015 was $140 million to $144 million. The also raising its adjusted earnings guidance for the full year 2015 to a range of $1.00 to $1.04 per share. Previously, the company's 2015 adjusted EPS guidance was $0.93-$0.97. Included in the company's revised 2015 earnings guidance are $4.4 million in non-cash stock-based compensation, $1.6 million in amortization of intangibles, between $1.5 million and $1.7 million for the U.S. medical device excise tax, and an assumed 36% tax rate. As previously disclosed, Vascular Solutions is providing 2015 earnings guidance on an adjusted basis excluding the expenses to be incurred in connection with the Short Kit litigation.

Vascular Solutions Seeks Acquisitions

Vascular Solutions Inc. (NasdaqGS:VASC) is seeking acquisitions. Howard Root, Chief Executive Officer, said, "We also continue to actively pursue opportunities to bring in new products through distribution agreements and tuck-in acquisitions, and typically have several opportunities under evaluation at any given time." Root added, "We're not looking to do transformational acquisitions in any way. It would have to be a really great deal for us to do that, given how well our base business is working."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VASC:US $32.39 USD -0.59

VASC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $18.31 USD -2.16
Cardiovascular Systems Inc $16.94 USD -0.21
CryoLife Inc $10.11 USD -0.16
Endologix Inc $12.61 USD -0.25
Spectranetics Corp/The $11.53 USD -0.98
View Industry Companies

Industry Analysis


Industry Average

Valuation VASC Industry Range
Price/Earnings 46.6x
Price/Sales 4.1x
Price/Book 4.7x
Price/Cash Flow 40.0x
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VASCULAR SOLUTIONS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at